Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-09-20
2005-09-20
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S199000, C514S322000, C514S326000, C514S331000, C546S210000, C546S231000
Reexamination Certificate
active
06946477
ABSTRACT:
One aspect of the present invention relates to novel heterocyclic compounds comprising urea functionality. A second aspect of the present invention relates to the use of the novel heterocyclic compounds comprising urea functionality as ligands for various cellular receptors, including opioid receptors, other G-protein-coupled receptors and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds comprising urea functionality as analgesics.
REFERENCES:
patent: 4181802 (1980-01-01), Kennis
patent: 4694004 (1987-09-01), Nakaguti et al.
patent: 4816465 (1989-03-01), Clemence et al.
patent: 5159081 (1992-10-01), Cantrell et al.
patent: 5270328 (1993-12-01), Cantrell et al.
patent: 5786448 (1998-07-01), Nefzi et al.
patent: 5840500 (1998-11-01), Pei et al.
patent: 5925527 (1999-07-01), Hayes et al.
patent: 6143895 (2000-11-01), Pei et al.
patent: 6262269 (2001-07-01), Hayes et al.
patent: 460 028 (1968-07-01), None
patent: 25 45 501 (1973-04-01), None
patent: 25 45 501 (1976-04-01), None
patent: 0 092 391 (1983-10-01), None
patent: 0 277 794 (1988-08-01), None
patent: 0 343 900 (1989-11-01), None
patent: 0 383 579 (1996-07-01), None
patent: 4208267 (1992-07-01), None
patent: WO 97/18813 (1997-05-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 00/21931 (2000-04-01), None
patent: WO 00/23438 (2000-04-01), None
patent: WO 00/71518 (2000-11-01), None
patent: WO 00/74679 (2000-12-01), None
patent: WO 01/12630 (2001-02-01), None
Baons et al.; “Synthesis of 2,5-Substituted Piperidines: Transposition of 1,4-Substitution Pattern for the analgesic Drug R6582”, Tetrahedron, NC, Elsevier Science Publishers, Amsterdam, 49(15): 3193-3202, (1993).
Crider et al.; “Synthesis of Nitrosourea Derivatives of Pyridine and Piperidine as Potential Anticancer Agents”, J. Med. Chem., 21, 848-851, (1980).
Harada et al.; “Development of Potent Serotonin-3 (5-HT 3) Receptor Antagonists. I. Structure- Activity Relationships of 2-Alkoxy-4 Amino-5 Chlorobenzamide derivatives”, Chem. Pharm. Bull. 43(8):1364-1378, (1995).
Mathison et al.; “N-[3-(1-Alkylpiperidyl)] Acetamides and N,N-Dimethyl-N′—[1-alkylpiperidyl)] ureas as Cholinesterase Inhibitors. 1”, J. Med. Chem. 12:928-931, (1969).
Chemical Abstracts, Columbus Ohio, US, No. XP-002171547, vol. 88(25), (1978), 88: 190835p; 3-Pyrrolidinylbenzimidazoline-2-ones. Hasegawa, Gen; Shiroki, Masami; Kotani, Akeshi. Japan—Kokai 78 09,770.
Chemical Abstract No. XP-002171548, vol. 76(21), (1972), 76: 126798d; Substituted piperidines. Irikura, Tsutomu; Kasuga, Kazunori; Segawa, Mitsuru. Japan—72 00,812.
Aquila Brian M.
Cuny Gregory D.
Hauske James R.
Shao Liming
Wu Xinhe
Foley & Hoag LLP
Gordon Dana M.
Johnsen Jason H.
Sepracor Inc.
Wilson James O.
LandOfFree
3-Substituted piperidines comprising urea functionality, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-Substituted piperidines comprising urea functionality, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-Substituted piperidines comprising urea functionality, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3375739